VA-CTA
2.4.2018 23:42:12 CEST | Business Wire | Press release
The Consumer Technology Association (CTA) today announced that CES Asia 2018 will highlight advancements in artificial intelligence (AI) as a new dedicated product category on the show floor, building on the successful demonstration of AI applications across the latest consumer tech products showcased at CES earlier this year.
Alibaba A.I. Labs, Baidu DuerOS and iFLYTEK, among others, will exhibit the latest in big data analytics, speech recognition and predictive technology. With China setting the pace to become a global innovation leader in AI, CES Asia will bring together the biggest players shaping the future of artificial intelligence.
“Artificial intelligence is one of those exciting technologies that will become ubiquitous in the next decade as it becomes more deeply embedded in the products that we use day in and day out to make our lives better, ” said John T. Kelley, senior director, international programs and show director, CES Asia. “AI is already being incorporated in everyday consumer technology products that provide practical benefits, including cars, smart homes, robotics, health and wellness devices and home security. China is leading the way in AI, embracing innovation and setting global standards and it will be front and center during CES Asia 2018!”
More, ARM Accelerator and the Hong Kong University of Science and Technology will bring several cutting-edge companies to CES Asia. IFLYTEK, who is currently valued at $6.3 billion USD, will return to the show floor as one of China’s most innovative tech companies. Cutting edge innovation in AI is also emerging from other Asian Countries. GT Robot Technology, a Singapore-based firm that specializes in humanoid robotic solutions, will exhibit at CES Asia for the first time.
“GT Wonder Boy is Singapore’s first SMART social bot companion, a reflection of Singapore’s shift towards a SMART Nation,” said Revathi, a spokesperson of GT Robot Technology Pte Ltd. “We are harnessing the power of technology in an era of digitisation, driving efficiency, creating something truly transformational.”
Other notable companies exhibiting include: Camsing Global, EMOS Technologies, Hangzhou Taruo Information Technology, HUMU Augmented Audio Cushion, Moran, Morpx, Sogou Teemo and Xvisio Technology.
Owned and produced by International CES (Shanghai) Exhibition Co. Ltd. and co-produced by Shanghai Intex, CES Asia 2018 will run from June 13-15, in Shanghai, China. The premier event for the consumer technology industry in Asia, CES Asia showcases major brands and innovative companies across several vertical markets in the Asian marketplace.
Visit CESAsia.com for the latest show news, information, photos, b-roll and more.
Note to Editors:
High-definition video b-roll from CES Asia 2017 is available for easy download on CESAsia.com . Journalists traveling from outside of China will require a J-1 or J-2 visa . For questions about exhibiting at CES Asia, contact Brian Moon at bmoon@CTA.tech or +1 703-907-4351.
About CES Asia:
Owned and produced by the International CES (Shanghai) Exhibition Co. Ltd. and co-produced by Shanghai Intex Exhibition Co., Ltd (Shanghai Intex), CES Asia is the premier event for the consumer technology industry, showcasing the full breadth and depth of the innovation value-chain in the Asian marketplace. Key global businesses come to this new event to grow and reinforce their brand by showcasing the latest products and technologies to consumer tech industry executives, foreign buyers, international media and a limited number of consumers from China. Attendees have exclusive access to some of the largest brands from China and around the world, while celebrating the innovation that defines the consumer technology sector.
About International CES (Shanghai) Exhibition Co. Ltd. and CTA:
International CES (Shanghai) Exhibition Co. Ltd. is a wholly foreign-owned enterprise by the Consumer Technology Association (CTA), a trade association representing the $321 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
About Shanghai Intex:
Shanghai Intex Exhibition Co., Ltd was originally the exhibition organizing business of Shanghai Intex, a pioneering exhibition organizer established in 1995. Shanghai Intex is jointly overseen by the China Council for the Promotion of International Trade (CCPIT) Shanghai and PNO Exhibition Investment (Dubai) Limited. Starting in 1998, Shanghai Intex has organized over 100 trade shows and conferences with a sum total exhibition space in excess of 2 million sqm. Shanghai Intex is comprised of professional teams with a wealth of experience in organizing major international events, covering the creative industry, healthcare, lifestyle, advanced manufacturing and consumer electronics.
UPCOMING EVENTS
-
CES on the Hill
April 16, Washington, DC -
Digital Patriots Dinner
April 17, Washington, DC -
CES Asia 2018 –
Register
June 13-15, Shanghai, China -
CEO Summit
June 24-27, Barcelona, Spain -
CES Unveiled Amsterdam
September 27, Amsterdam, Netherlands -
CES 2019
January 8-11, Las Vegas, NV
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005890/en/
Contact:
Consumer Technology Association
Teresa Hsu, 703-907-5259
thsu@CTA.tech
www.CESAsia.com
or
Bernice
Morquette, 703-907-7651
bmorquette@CTA.tech
www.CES.tech
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom